GM suffers a sales drop; Novartis announces positive results from its study of an osteoporosis treatment; plus more stocks in the news Thursday
UBS UBS posts net profit attributable to UBS shareholders of CHF 3,275 million, down CHF 229 million from the same period a year earlier.
General Motors GM Posts $0.11 vs. $1.06 first quarter EPS (GAAP) on a 16% drop in total net sales and revenues; announces losses at GMAC Financial Services.
Novartis NVS Says once-yearly treatment of Reclast Injection greatly reduced the incidence of osteoporotic bone fractures over three years in women with postmenopausal osteoporosis. Notes that there was a rise in serious atrial fibrillation vs. a placebo.
Gartner IT Posts $0.08 vs. $0.07 first quarter EPS on a 14% total revenue rise. To reflect strength in the business, now targets $1.160 million to $1.187 million 2007 total revenue and $0.70 to $0.77 EPS.
Symantec SYMC Posts $0.24 vs. $0.26 fourth quarter non-GAAP EPS as higher operating costs offset a 5% revenue rise. Sees first quarter EPS of $0.18 to $0.20 on $1.295 billion to $1.325 billion revenue; sees $1.10 to $1.15 fiscal year 2008 EPS on $5.65 billion to $5.75 billion revenue.
Verisign VRSN Posts $378.6 million vs. $372.8 million first quarter revenue.
Estee Lauder EL Posts lower-than-expected $0.45 vs. $0.29 third quarter EPS from continuing operations on a 7% sales rise.